

Collaborative Working Executive Summary

Project Name

The Meon Secondary Prevention Service

Between

The Meon Health Practice, Health Innovation Wessex, Suvera

And

Recordati Pharmaceuticals Ltd

Project Start

January 2026

Duration

6 Months

Project Summary

The Meon Health Practice (MHP) working with Health Innovation Wessex (HIW) identified that a number of their patients are not currently optimised for Cardiovascular Secondary Prevention risk factors in line with the current National and Hampshire Guidelines which were updated in 2025. These risk factors include uncontrolled Hypertension, LDL Cholesterol and residual CV risk indicated by elevated triglycerides.

Following discussions between HIW and MHP it was identified that there may be more efficient ways to manage these patients and also to improve access to Secondary Prevention CVD Services for MHP patients in higher deprivation areas by working with additional partners which has led to this project.

As this project will pilot a new way of working within CVD Secondary Prevention in Wessex, HIW will provide an independent evaluation to assess the project's effectiveness in achieving its goals.

The Project will consist of the following and be set up and run by the Collaborators and partly funded by Recordati.

The service will use the Suvera Clinical Team, overseen by Suvera GP's, to review and optimise the patients across a range of CV risk factors, including blood pressure, LDL Cholesterol and residual CV risk indicated by elevated triglycerides, in line with the National and Hampshire Secondary Prevention Guidelines with the aim of reducing the patient's risk of a future CV event.

Project Benefits

For Patients

- Improved clinical care for patients, through proactive identification of at-risk Patients and optimisation secondary prevention therapies in line with Guidelines.
- Greater satisfaction of patients due to improved identification and proactive management of their cardiovascular risk through the additional capacity provided by the Secondary Prevention Service.
- Improved access to testing through the provision of PocDoc Point of Care testing if patients find accessing standard services difficult.

For MHP

- The Service may lead to reduction in recurrent cardiac events, with eventual medium and long-term saving for NHS and reduction in the downstream burden on the health system (e.g. hospitalisation) from recurrent cardiac events.
- The Service may lead to an increase in the number of patients achieving the Quality and Outcomes (QoF) framework targets for cardiovascular disease which may increase the QoF points achieved.

For HIW

- Supporting the local healthcare system with their strategic focuses on CVD and health inequalities.
- Increasing the percentage of secondary prevention patients treated to target, which may in turn reduce the number of additional events, alleviate pressure on the wider healthcare system and improve quality of life.

For Recordati

- Increase in the appropriate use of medicines aligned with local and national guidance which includes Recordati's product.
- Increase in Patients identified and treated for secondary CVD risk factors, which may be relevant to the Recordati business.
- Increased knowledge about the identification and management of secondary prevention patients especially in relation to lipids.
- Increased knowledge about patient choices and reasons for declining evidencebased treatment options.
- Enhanced Recordati reputation and supporting the Recordati Mantra that

“health, and the opportunity to live life to the fullest, is a right, not a privilege.”

Financial Contribution

It is estimated that the total cost, direct and indirect, of the project is £56,600.

Recordati are contributing 41.1% of the total cost.

Recordati have agreed to fund additional capacity to review these patients at a cost of £20,000.

Recordati will also cover the costs of 100 PocDoc Tests for use during the project at a cost of £1410 as well as providing project management support.

Meon Health Partnership are covering the cost of premises, blood tests, IT, patient information systems, training and supervision of clinical staff.

Suvera are covering the costs of their IT systems , governance, supervision, education and training of their staff.

Health Innovation Wessex are, through their evaluations team, producing an independent project evaluation as well as providing ongoing project management.

UK-VAZK-0105

Date of preparation January 2026